Pfizer (XSWX:PFE) Cash Flow for Lease Financing: CHF0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:PFE Pfizer Inc XSWX:PFE
60 GF Score
Price CHF22.37
GF Value CHF21.66
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Pfizer Cash Flow for Lease Financing?

Pfizer XSWX:PFE 60 Cash Flow for Lease Financing is CHF0 Mil as of Jun. 2026. GuruFocus rates XSWX:PFE with a GF Score™ of 60/100 and a GF Value™ of CHF21.66 (Fairly Valued). The stock has 8 warning signs investors should review.

Pfizer's Cash Flow for Lease Financing for the three months ended in Jun. 2026 was CHF0 Mil. Pfizer's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jun. 2026 was CHF0 Mil.

Compared with last quarter (CHF0 Mil in Mar. 2026 ), Pfizer's Cash Flow for Lease Financing remained the same in Jun. 2026 (CHF0 Mil).

Pfizer Cash Flow for Lease Financing Historical Data

* Premium members only.

The historical data trend for Pfizer's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Cash Flow for Lease Financing Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pfizer Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:PFE
60GF Score
Pfizer Inc XSWX:PFE
Cash Flow for Lease Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Lease Financing of CHF0 Mil mean?
Pfizer (XSWX:PFE) has a Cash Flow for Lease Financing of CHF0 Mil as of Jun. 2026. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on Pfizer and its competitors.
Is Pfizer's Cash Flow for Lease Financing too high?
Pfizer's current Cash Flow for Lease Financing is CHF0 Mil. Overall, Pfizer has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Cash Flow for Lease Financing compare to GILD and BMY?
Pfizer's Cash Flow for Lease Financing of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Lease Financing for a Drug Manufacturers company?
A good Cash Flow for Lease Financing depends on the Drug Manufacturers industry context. However, Cash Flow for Lease Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Lease Financing mean?
A high Cash Flow for Lease Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on Pfizer and its competitors. Pfizer's current Cash Flow for Lease Financing is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF21.66, compared to a current price of CHF22.37 — trading 3.3% above its estimated fair value. The current Cash Flow for Lease Financing is CHF0 Mil. Pfizer's overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Lease Financing calculated?
Cash Flow for Lease Financing is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current Cash Flow for Lease Financing is CHF0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (XSWX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be overvalued. The current stock price of CHF22.37 is trading 3.3% above its estimated GF Value™ of CHF21.66. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for XSWX:PFE:

  • Cash Flow for Lease Financing: CHF0 Mil
  • GF Value™: CHF21.66 vs. price of CHF22.37 (3.3% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
60GF Score

Get the complete analysis for XSWX:PFE

Cash Flow for Lease Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF22.37
Price
CHF21.66
GF Value